Trial Profile

A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; RG 4733 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Glioma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer
Focus Adverse reactions

Most Recent Events

22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
17 Jul 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
11 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 May 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com